Table 1.
Cohort characteristics
| Characteristic (n%) | Total Cohort (n=212) | HIV-Negative (n=94) | HIV-Positive (n=118) | p-value |
|---|---|---|---|---|
| Age (mean/SD) | 51.7 (7) | 52.2(6.9) | 51.3(7.1) | 0.324 |
| Female | 102 (48.1) | 45 (47.8) | 57 (48.3) | 0.95 |
| BMI (Mean/SD) | 22.7 (4.2) | 22.4 (4.5) | 22.8 (3.9) | 0.431 |
| <18.5 | 21(9.9) | 14 (14.8) | 7 (6.0) | 0.099 |
| 18.5 – 24.9 | 142 (67.0) | 62 (66.0) | 80 (67.8) | |
| 25.0 – 29.9 | 34 (16.0) | 11 (11.7) | 23 (19.5) | |
| ≥30 | 15 (7.1) | 7 (7.5) | 8 (6.8) | |
| FPG (mean/SD) | 89.7(33.2) | 91.2 (34.2) | 88.5 (32.5) | 0.554 |
| <100mg/dl | 180 (84.9) | 77 (81.9) | 103 (87.3) | 0.553 |
| 100–125 mg/dl | 19 (9.0) | 10 (10.6) | 9 (7.6) | |
| ≥126 mg/dl | 13 (6.2) | 7 (7.45) | 6 (5.1) | |
| A1c | 5.6 (1.1) | 5.6 (0.96) | 5.5 (1.2) | 0.687 |
| <5.7% | 156 (73.6) | 62 (66.0) | 94 (79.7) | 0.024* |
| 5.7–6.4% | 43 (20.3) | 27 (28.7) | 16 (13.6) | |
| ≥6.5% | 13 (6.1) | 5 (5.3) | 8 (6.8) | |
| ART Therapy | ||||
| AZT/3TC/NVP | 100 (64.5) | |||
| AZT/3TC/EFV | 41 (26.5) | |||
| TDF/3TC/LPV/R | 10 (6.5) | |||
| Other | 4 (2.5) | |||
| CD4 count (Median/IQR) | 485 (837) | |||
| Nadir CD4 (Median/IQR) | 131 (432) |
*
Statistically significant at 0.05 level